Current Grants

Johnson & Johnson
Horvath N, To LB, Zannettino ACW
BIR (Bortezomib Induction and Reinduction) Study
2004 – 2006 $148,625

Leukaemia and Lymphoma Society, USA
D’Andrea RJ, Gonda TJ, Bardy P, To LB, Lewis ID
Identification of growth factor receptor mutations in Polycythemia vera
2004 – 2006 $169,730

National Health & Medical Research Council
Zannettino A, To L, Atkins G, Findlay D
Molecular and cellular mechanisms of skeletal disease mediated by plasma cell dyscrasias
2004 – 2006 $141,750

Pharmion
Lewis I, Szabo F, Goodall G, Tsykin A, Rawling T
Gene expression profile in patients with high risk myelodysplastic syndromes treated with azacitidine or best supportive care.
2006 - $30,000

RAH Contributing Haematologists Committee
Lewis I, To LB, Dyson P, Hiwase S, Gronthos S
Development of Mesenchymal Stem Cell Expansion for use in Clinical
Transplantation Studies
2004 - $30,292

Lewis I, To LB, Gillis D, Al-Mawali A
Detection of Minimal Residual Disease in Acute Myeloid Leukaemia Using Multiparameter Flow Cytometry
2005 - $29,905

Fitter S, Zannettino A, To LB
Development of a therapeutic aptamer that antagonises SDF-1α (CXCX12 binidng to CXCR4)
2006 - $27,004

Cancer Council of South Australia
‘Causes and significance of persistent leukaemia in CML patients treated with ABL kinase inhibitors
2005/2006 - $136,514

Novartis Leukaemia Research Grant
2005/2006 - $350,000

NHMRC Infrastructure support for the Australasian Leukaemia and Lymphoma Group Trial Centre.
‘Lymphoma, leukaemia and related cancers of the blood affect thousands of Australians including children. The Australasian Leukaemia and Lymphoma Group will integrate laboratory research to discover new approaches to treatment’
Co-investigator Timothy Hughes
2005/2010 - $790,000

Novartis AMN Study
2006 - $170,200

National Health and Medical Research Council Project Grant 453509. ‘The role of intracellular uptake and retention of ABL kinase inhibitors in modifying clinical response in CML
2007/2009 - $149,000 per year